Entrectinib (CAS 1108743-60-7)
Alternate Names:
RXDX-101; RXDX101; RXDX 101; Rozlytrek; NMS-E628; NMS E628
CAS Number:
1108743-60-7
Molecular Weight:
560.60
Molecular Formula:
C31H34F2N6O2
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Entrectinib (CAS 1108743-60-7) References
- Comprehensive Review of ROS1 Tyrosine Kinase Inhibitors-Classified by Structural Designs and Mutation Spectrum (Solvent Front Mutation [G2032R] and Central β-Sheet 6 [Cβ6] Mutation [L2086F]). | Ou, SI., et al. 2024. J Thorac Oncol. 19: 706-718. PMID: 38070596
- ETV6-NTRK2 Fusion in a Patient With Metastatic Pulmonary Atypical Carcinoid Successfully Treated With Entrectinib: A Case Report and Review of the Literature. | Zhang, W., et al. 2024. Clin Lung Cancer. 25: 215-224.e3. PMID: 38584068
- Acquired NF2 mutation confers resistance to TRK inhibition in an ex vivo LMNA::NTRK1-rearranged soft-tissue sarcoma cell model. | Chen, Y., et al. 2024. J Pathol. 263: 257-269. PMID: 38613194
- Inhibition of human UDP-glucuronosyltransferase enzyme by entrectinib: Implications for drug-drug interactions. | Yin, H., et al. 2024. Chem Biol Interact. 395: 111023. PMID: 38677539
- Entrectinib as first-line vs. second-line therapy in ROS1 fusion-positive non-small cell lung cancer: a cost-effectiveness analysis. | Huo, G., et al. 2024. Transl Lung Cancer Res. 13: 839-848. PMID: 38736499
- Healthcare decision-making for tumour-agnostic therapies in Europe: lessons learned. | Hogervorst, MA., et al. 2024. Drug Discov Today. 29: 104031. PMID: 38796096
- Transforming tumoroids derived from ALK-positive pulmonary adenocarcinoma to squamous cell carcinoma in vivo. | Yokota, E., et al. 2024. Hum Cell. 37: 1132-1140. PMID: 38829559
- Repurposing FDA-approved compounds to target JAK2 for colon cancer treatment. | Chandrasekhar, B., et al. 2024. Discov Oncol. 15: 226. PMID: 38869738
- Entrectinib in ROS1-positive advanced non-small cell lung cancer: the phase 2/3 BFAST trial. | Peters, S., et al. 2024. Nat Med.. PMID: 38898120
- Induction of resistance to neurotrophic tropomyosin-receptor kinase inhibitors by HMGCS2 via a mevalonate pathway. | Kato, Y., et al. 2024. Cancer Med. 13: e7393. PMID: 38923428
- Clinical characteristics and treatment patterns of patients with NTRK fusion-positive solid tumors: A multisite cohort study at US academic cancer centers. | Willis, C., et al. 2024. J Manag Care Spec Pharm. 30: 672-683. PMID: 38950155
- Efficacy and safety of NTRK inhibitors in patients with NTRK fusion-positive lung and thyroid cancers. | Hong, DS., et al. 2024. Clin Adv Hematol Oncol. 22 Suppl 5: 1-20. PMID: 38953725
- Discovery of a first-in-class protein degrader for the c-ros oncogene 1 (ROS1). | Yang, J., et al. 2024. Bioorg Chem. 150: 107590. PMID: 38955003
Inhibitor of:
FAM150A, Olr694, TRBV3, Trk A, TRK-T3, TrkA family transport protein, and Twinfilin-2.Activator of:
ALK, Pdcd-1, and Trk C.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Entrectinib, 5 mg | sc-507438 | 5 mg | $180.00 |